secwatch.observer — SEC 8-K summary
======================================

Issuer:     ORAGENICS INC (OGEN)
CIK:        0001174940
Form:       8-K
Filed at:   2024-12-16T23:59:59+00:00
Accession:  0001493152-24-050216
Event type: leadership
Sentiment:  neutral
Materiality: 0.75
Item codes: 5.02, 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oragenics appoints CFO Janet Huffman as Interim CEO; Preferred conversion cancels $2.35M liquidation preference
--------------------------------------------------------------------------------

- J. Michael Redmond terminated as Interim CEO/President effective Dec 16, 2024; CFO Janet Huffman appointed as new Interim CEO and President.
- Shareholders approved increasing 2021 Equity Incentive Plan by 2M shares to total 3,166,667 shares.
- All remaining Series A (5,417,000) and Series B (4,050,000) preferred shares converted to ~22,000 common shares, eliminating $2.35M liquidation preference.
- Directors re-elected: Charles Pope, Frederick Telling, Alan Dunton, Robert Koski, John Gandolfo, Bruce Cassidy.
- Advisory vote on executive compensation passed with 1,931,906 for vs 365,871 against.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1174940/000149315224050216/0001493152-24-050216-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1174940/000149315224050216/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-050216

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer